Immunovant, INC 10-Q quarterly reports

Immunovant Inc. reported its second-quarter 2026 financial results, highlighting increased research and development expenses and a continued net loss, while emphasizing the strategic focus on its lead asset, IMVT-1402.

Immunovant reports a strong cash position of nearly $1 billion following a recent equity offering, while advancing its lead asset IMVT-1402 into multiple registrational trials for autoimmune diseases.

Immunovant reports increased net loss in Q2 2025 as it accelerates development of its lead FcRn inhibitor, IMVT-1402, across multiple autoimmune indications.

Immunovant, Inc. reported increased net losses and cash burn in Q1 2025 as it significantly expanded its clinical pipeline for IMVT-1402, initiating multiple potentially registrational trials.

Immunovant's Q3 2025 report reveals a net loss of $111.1 million, alongside advancements in IMVT-1402 clinical programs.

Immunovant's Q2 2025 report highlights increased R&D spending as the company advances its IMVT-1402 clinical programs and provides updates on batoclimab trials.

Immunovant, a clinical-stage immunology company, announced its financial results for the quarter ended June 30, 2024, and provided an update on its clinical development programs, particularly for IMVT-1402.

Immunovant, a clinical-stage biopharmaceutical company, released its third quarter results for fiscal year 2024, showcasing advancements in its batoclimab and IMVT-1402 clinical programs.